檢索結果 - Adewoye, Adeboye

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study 由 Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy

獲取全文 獲取全文 獲取全文

Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-β/BMP Pathway: —Sickle Cell Leg Ulcers, Genetics and Haemolysis— 由 Nolan, Vikki G., Adewoye, Adeboye, Baldwin, Clinton, Wang, Ling, Ma, Qianli, Wyszynski, Diego F., Farrell, John J., Sebastiani, Paola, Farrer, Lindsay A., Steinberg, Martin H.

獲取全文 獲取全文 獲取全文

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer 由 De Boer, Richard H., Kotasek, Dusan, White, Shane, Koczwara, Bogda, Mainwaring, Paul, Chan, Arlene, Melara, Rebeca, Ye, Yining, Adewoye, Adeboye H., Sikorski, Robert, Kaufman, Peter A.

獲取全文 獲取全文 獲取全文

Sickle Cell Vaso-occlusive Crisis Induces the Release of Circulating Serum Heat Shock Protein-70 由 Adewoye, Adeboye H., Klings, Elizabeth S., Farber, Harrison W., Palaima, Elizabeth, Bausero, Maria A., McMahon, Lillian, Odhiambo, Adam, Surinder, Safaya, Yoder, Mark, Steinberg, Martin H., Asea, Alexzander

獲取全文 獲取全文 獲取全文

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies 由 Kater, Arnon P., Tonino, Sanne H., Spiering, Marjolein, Chamuleau, Martine E. D., Liu, Roberto, Adewoye, Adeboye Henry, Gao, Jie, Dreiling, Lyndah, Xin, Yan, Doorduijn, Jeanette K., Kersten, Marie José

獲取全文 獲取全文 獲取全文

Evaluation of the CLL-IPI in Relapsed and Refractory Chronic Lymphocytic Leukemia in Idelalisib Phase 3 Trials 由 Soumerai, Jacob D., Ni, Ai, Xing, Guan, Huang, Julie, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., Hallek, Michael, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah, Zelenetz, Andrew D.

獲取全文 獲取全文 獲取全文

A network model to predict the risk of death in sickle cell disease 由 Sebastiani, Paola, Nolan, Vikki G., Baldwin, Clinton T., Abad-Grau, Maria M., Wang, Ling, Adewoye, Adeboye H., McMahon, Lillian C., Farrer, Lindsay A., Taylor, James G., Kato, Gregory J., Gladwin, Mark T., Steinberg, Martin H.

獲取全文 獲取全文 獲取全文

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro... 由 Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter

獲取全文 獲取全文 獲取全文